With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly’s next twelve months forward P/E ratio, investors are paying ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly ... in 2019. Lilly is thought to be the first pharma company to sign up to ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the ...

Drugmaker Eli Lilly signed an agreement with the U.K. government to support early-stage life sciences businesses in the country. As part of the collaboration, which was announced Monday at the U.K.'s ...